The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients

References

• The Precision Medicine Initiative [cited 2016 Mar 10]. No data on web-page update. Available from: https://www.whitehouse.gov/precision-medicine.
   Google Scholar
• All about the Human Genome Project (HGP) [updated 2015 Oct 1; cited 2016 Mar 10]. Available from: http://www.genome.gov/10001772.
   Google Scholar
• Saini R, Saini S, Sugandha RS. Pharmacogenetics: the future medicine. J Adv Pharm Technol Res. 2010;1:423–424.
   PubMedGoogle Scholar
• Nelson DR, Zeldin DC, Hoffman SM, et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics. 2004;14:1–18.
   PubMedGoogle Scholar
• Nakajima M, Kobayashi K, Shimada N, et al. Involvement of CYP1A2 in mexiletine metabolism. Br J Clin Pharmacol. 1998;46:55–62.
   PubMed Web of Science ®Google Scholar
• Corrigan BW, Nicholls B, Thakrar B, et al. Heterogeneity in systemic availability of ondansetron and granisetron following oral administration. Drug Metab Dispos. 1999;27:110–112.
   PubMed Web of Science ®Google Scholar
• Lehmann DE. Enzymatic shunting: resolving the acetaminophen-warfarin controversy. Pharmacotherapy. 2000;20:1464–1468.
   PubMed Web of Science ®Google Scholar
• Gu J, Su T, Chen Y, et al. Expression of biotransformation enzymes in human fetal olfactory mucosa: potential roles in developmental toxicity. Toxicol Appl Pharmacol. 2000;165:158–162.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996;6:1–42.
   PubMedGoogle Scholar
• Imaoka S, Yamada T, Hiroi T, et al. Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol. 1996;51:1041–1050.
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414–423.
   PubMed Web of Science ®Google Scholar
• Eichelbaum M, Spannbrucker N, Steincke B, et al. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979;16:183–187.
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther. 1992;51:388–397.
   PubMed Web of Science ®Google Scholar
• Daly AK, Brockmöller J, Broly F, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics. 1996;6:193–201.
   PubMedGoogle Scholar
• Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A. 1993;90:11825–11829.
   PubMed Web of Science ®Google Scholar
• McLellan RA, Oscarson M, Seidegård J, et al. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics. 1997;7:187–191.
   PubMedGoogle Scholar
• Kashuba DMA, Bertino JS Jr. Mechanisms of drug interactions. Drug interactions in infectious diseases. 1st ed. Totowa (NJ): Humana Press; 2000. p. 13–38.
   Google Scholar
• Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001;299:825–831.
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383–391.
   PubMed Web of Science ®Google Scholar
• Janicki PK. Pharmacogenomics of pain management. In: Deer TR, Leong MS, Buvanendran A, et al., eds. Comprehensive treatment of chronic pain by medical, interventional, and integrative approaches: the American academy of pain medicine textbook on patient management. New York (NY): Springer Publishing Company; 2013. p. 23–33.
   Google Scholar
• P450 Drug Interaction Table [cited 2016 Mar 10]. Available from: http://medicine.iupui.edu/clinpharm/ddis/main-table/.
   Google Scholar
• Wang B, Yang L-P, Zhang X-Z, et al. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev. 2009;41:573–643.
   PubMed Web of Science ®Google Scholar
• Zhou S-F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 2009;48:689–723.
   PubMed Web of Science ®Google Scholar
• Zhou S-F, Liu J-P, Lai X-S. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr Med Chem. 2009;16:2661–2805.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics and biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:23–37.
   PubMed Web of Science ®Google Scholar
• Bernard S, Neville KA, Nguyen AT, et al. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist. 2006;11:126–135.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999;20:342–349.
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83:234–242.
   PubMed Web of Science ®Google Scholar
• Borges S, Desta Z, Jin Y, et al. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol. 2010;50:450–458.
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Gotschall RR, Forbes NS, et al. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics. 1999;9:669–682.
   PubMedGoogle Scholar
• Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95:376–382.
   PubMed Web of Science ®Google Scholar
• Thorn CF, Klein TE, Altman RB. Codeine and morphine pathway. Pharmacogenet Genom. 2009;19:556–558.
   PubMed Web of Science ®Google Scholar
• Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351:2827–2831.
   PubMed Web of Science ®Google Scholar
• Eckhardt K, Li S, Ammon S, et al. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain. 1998;76:27–33.
   PubMed Web of Science ®Google Scholar
• Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther. 1993;53:401–409.
   PubMed Web of Science ®Google Scholar
• Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229–243.
   PubMed Web of Science ®Google Scholar
• Poulsen L, Brøsen K, Arendt-Nielsen L, et al. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol. 1996;51:289–295.
   PubMed Web of Science ®Google Scholar
• Lotsch J, Skarke C, Schmidt H, et al. Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites. Clin Pharmacol Ther. 2006;79:35–48.
   PubMed Web of Science ®Google Scholar
• Madadi P, Amstutz U, Rieder M, et al. Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. J Popul Clin Pharmacol. 2013;20:e369–e396.
   Google Scholar
• VanderVaart S, Berger H, Sistonen J, et al. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study. Ther Drug Monit. 2011;33:425–432.
   PubMed Web of Science ®Google Scholar
• Kelly LE, Rieder M, Van den Anker J, et al. More codeine fatalities after tonsillectomy in North American children. Pediatrics. 2012;129:e1343–e1347.
   PubMed Web of Science ®Google Scholar
• Madadi P, Koren G, Cairns J, et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician. 2007;53:33–35.
   PubMed Web of Science ®Google Scholar
• Sistonen J, Madadi P, Ross CJ, et al. Prediction of codeine toxicity in infants and their mothers using novel combination of maternal genetic markers. Clin Pharmacol Ther. 2012;91:692–699.
   PubMed Web of Science ®Google Scholar
• Ciszkowski C, Madadi P, Phillips MS, et al. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med. 2009;361:827–828.
   PubMed Web of Science ®Google Scholar
• Voronov P, Przybylo HJ, Jagannathan N. Apnea in a child after oral codeine: a genetic variant- an ultra-rapid metabolizer. Paediatr Anaesth. 2007;17:684–687.
   PubMed Web of Science ®Google Scholar
• Koren G, Cairns J, Chitayat D, et al. Pharmacolgenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006;368:704.
   PubMed Web of Science ®Google Scholar
• Ferreirós N, Dresen S, Hermanns-Clausen M, et al. Fatal and severe codeine intoxication in 3-year-old twins – interpretation of drug and metabolite concentrations. Int J Legal Med. 2009;123:387–394.
   PubMed Web of Science ®Google Scholar
• Madadi P, Avard D, Koren G. Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation. Curr Drug Metab. 2012;13:721–727.
   PubMed Web of Science ®Google Scholar
• Dalén P, Frengell C, Dahl ML, et al. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit. 1997;19:543–544.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Safety review update of codeine use in children; new boxed warning and contraindication on use after tonsillectomy and/or adenoidectomy. FDA Drug Safety Communication [cited 2016 Mar 10]. Available from: http://www.fda.gov/drugs/drugsafety/ucm339112.htm.
   Google Scholar
• Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J Pharmacol Exp Ther. 1992;260:275–285.
   PubMed Web of Science ®Google Scholar
• Lintz W, Barth H, Osterloh G, et al. Bioavailability of enteral tramadol formulations. Arzneimittelforschung. 1986;636:1278–1283.
   Google Scholar
• Lintz W, Erlaçin S, Frankus E, et al. Metabolismus von Tramadol bei Mensch und Tier. Arzneimittelforschung. 1981;31:1932–1943.
   PubMed Web of Science ®Google Scholar
• Garrido MJ, Valle M, Campanero MA, et al. Modeling of the in vivo antinociceptive interaction between an opioid agonist, (+)- O-desmethyltramadol, and a monoamine reuptake inhibitor, (−)-O-desmethyltramadol, in rats. J Pharmachol Exp Ther. 2000;295:352–359.
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Keulen JT, Bauer S, et al. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol. 2008;28:78–83.
   PubMed Web of Science ®Google Scholar
• Stamer UM, Stüber F, Muders T, et al. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg. 2008;107:926–929.
   PubMed Web of Science ®Google Scholar
• Müller B, Wilsmann K. Cardiac and hemodynamic effects of the centrally acting analgesics tramadol and pentazocine in anesthetized rabbits and isolated guinea-pig atria and papillary muscles. Arzneimittelforschung. 1984;34:430–433.
   PubMed Web of Science ®Google Scholar
• Raimundo JM, Pontes LB, Antunes F, et al. In vitro and in vivo vasodilatory activity of racemic tramadol and its enantiomers in Wistar rats. Eur J Pharmacol. 2006;530:117–123.
   PubMed Web of Science ®Google Scholar
• Raimundo JM, Pontes LB, Antunes F, et al. Comparative effects of tramadol on vascular reactivity in normotensive and spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 2008;35:1197–1203.
   PubMed Web of Science ®Google Scholar
• Bozkurt P. Use of tramadol in children. Paediatr Anaesth. 2005;15:1041–1047.
   PubMed Web of Science ®Google Scholar
• Vuilleumier PH, Stamer UM, Landau R. Pharmacogenomic considerations in opioid analgesia. Pharmgenomics Pers Med. 2012;5:73–87.
   PubMedGoogle Scholar
• Simasek M, Blandino DA. Treatment of the common cold. Am Fam Physician. 2007;75:515–520.
   PubMed Web of Science ®Google Scholar
• Stolz D, Chhajed PN, Leuppi JD, et al. Cough suppression during flexible bronchoscopy using combined sedation with midazolam and hydrocodone: a randomized, double blind, placebo controlled trial. Thorax. 2004;59:773–776.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA takes action to stop marketing of unapproved hydrocodone products: action to impact approximately 200 cough-suppressant products [press release] [cited 2016 Mar 10]. Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108997.htm.
   Google Scholar
• Mitka M. FDA bans sale of unapproved cough suppressants containing hydrocodone. Jama. 2007;298:2165–2171.
   Web of Science ®Google Scholar
• Cone EJ, Darwin WD, Gorodetzky CW, et al. Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbits, and dog. Drug Metab Dispos. 1978;6:488–493.
   PubMed Web of Science ®Google Scholar
• Otton SV, Schadel M, Cheung SW, et al. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther. 1993;54:463–472.
   PubMed Web of Science ®Google Scholar
• Hutchinson MR, Menelaou A, Foster DJ, et al. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004;57:287–297.
   PubMed Web of Science ®Google Scholar
• Cone EJ, Darwin WD. Simultaneous determination of hydromorphone, hydrocodone and 6alpha- and 6beta-hydroxy metabolites in urine using selected ion recording with methane chemical ionization. Biomed Mass Spectrom. 1978;5:291–295.
   PubMedGoogle Scholar
• Madadi P, Hildebrandt D, Gong IY, et al. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. Pediatrics. 2010;126:e986–9.
   PubMed Web of Science ®Google Scholar
• Lalovic B, Phillips B, Risler LL, et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004;32:447–454.
   PubMed Web of Science ®Google Scholar
• Chen ZR, Irvine RJ, Somogyi AA, et al. Mu receptor binding of some commonly used opioids and their metabolites. LifeSci. 1991;48:2165–2171.
   Web of Science ®Google Scholar
• Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79:461–479.
   PubMed Web of Science ®Google Scholar
• Samer CF, Daali Y, Wagner M, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 andCYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol. 2010;160:919–930.
   PubMed Web of Science ®Google Scholar
• Maddocks I, Somogyi A, Abbott F, et al. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage. 1996;12:182–189.
   PubMed Web of Science ®Google Scholar
• Myers AB, Sullivan JE, Koller DM, et al. Correlation of CYP2D6 genotype with response to oxycodone in orthopedic injury related pain. Clin Pharmacol Ther. 2005;79:P18.
   Google Scholar
• Susce MT, Murray-Carmichael E, de Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1356–1358.
   PubMed Web of Science ®Google Scholar
• Foster A, Mobley E, Wang Z. Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract. 2007;7:352–356.
   PubMedGoogle Scholar
• de Leon J, Dinsmore L, Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol. 2003;23:420–421.
   PubMed Web of Science ®Google Scholar
• Nieminen TH, Hagelberg NM, Saari TI, et al. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology. 2009;110:1371–1378.
   PubMed Web of Science ®Google Scholar
• Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther. 1998;64:603–611.
   PubMed Web of Science ®Google Scholar
• Andreassen TN, Eftedal I, Klepstad P, et al. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. Eur J Clin Pharmacol. 2012;68:55–64.
   PubMed Web of Science ®Google Scholar
• Zwisler ST, Enggaard TP, Mikkelsen S, et al. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol Scand. 2010;54:232–240.
   PubMed Web of Science ®Google Scholar
• Lemberg KK, Heiskanen TE, Neuvonen M, et al. Does co-administration of paroxetine change oxycodone analgesia: an interaction study in chronic pain patients. Scand J Pain. 2010;1:24–33.
   Google Scholar